Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amnion + endometrium cells refers to a combination cell therapy utilizing cells derived from the amniotic membrane (typically human amniotic epithelial cells, hAECs) and the endometrium (typically endometrial mesenchymal stem cells, EnMSCs). This combination is primarily investigated for regenerative medicine applications in gynecology and reproductive health, specifically for treating premature ovarian failure (POF) and Asherman's syndrome. The therapeutic rationale is based on the synergistic effects of both cell types: amniotic cells provide potent immunomodulatory and anti-inflammatory properties, while endometrial stem cells offer high proliferative capacity and the ability to promote angiogenesis and tissue regeneration within the uterine or ovarian environment. Clinical research often involves the co-transplantation of these cells or the use of the amniotic membrane as a biological scaffold for endometrial stem cell delivery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amnion + endometrium cells.